Polyendocrine metabolic ovarian syndrome: A new name to improve diagnosis, care of condition affecting 170 million women

AI Summary

A global initiative led by Monash University has renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome (PMOS) to enhance diagnosis and care. This condition affects over 170 million women worldwide, demonstrating a critical need for updated understanding and management strategies.

A global effort led by Monash University has changed the name of a significant women's health condition that was misunderstood to be "all about ovarian cysts." Polyendocrine metabolic ovarian syndrome (PMOS) is the new name for the condition previously known as polycystic ovary syndrome (PCOS), which impacts one in eight, or more than 170 million women worldwide.